Praesentia Healthcare has re-entered the market with BDO Canada to seek USD 200m–USD 220m in debt financing to support M&A across North America, according to CEO and sole owner Hany Demian.

The company is in discussions with US and Canadian banks and is seeking an additional line of credit on top of existing debt, also for acquisitions, Demian said. To continue fueling organic and inorganic growth, Praesentia plans to explore a minority stake sale within the next 12 months, alongside BDO and will likely cede around one-third of the business, he added.

Demian, who told this news service in November 2024 that the Toronto-based company had launched a process, said it was shelved last year as Praesentia expanded from traditional chronic pain management and spinal surgery into the larger and fast-growing longevity, anti-aging, and personalized medicine market.

Last month, as part of its pivot, Praesentia sold its US-based BioSpine business to Regent Surgical Health. The deal, which consisted of seven Central Florida spine surgery practice locations, including two minimally invasive surgical centers, was valued at close to USD 100m, Demian said. Praesentia acquired BioSpine in January 2024 as an entry into the US.

Praesentia generated revenue of about USD 90m and EBITDA of roughly USD 15m-USD 16m in 2025, according to Demian. At least 30% growth is forecast this year, he said.

Praesentia owns and operates 12 Pain Care Clinics and two Alfa Scan Diagnostic Imaging centers in Ontario. It is building its first personalized medicine and surgical center in Toronto, called LifeSpan Bioscience. Offerings will include stem cell injections, supplement support, and peptide and platelet-rich plasma therapy, as well as remote patient monitoring.

Within the next couple of months, Praesentia expects to close two US ambulatory surgery center (ASC) acquisitions in Miami and Fort Lauderdale, both of which will be converted into LifeSpan Bioscience centers.

Demian noted that the Florida state legislature last year loosened certain restrictions on stem cell therapies, allowing licensed doctors to offer some non-FDA-approved stem cell treatments that can be used to repair, replace, or regenerate damaged cells and tissues.

Praesentia will look to acquire two additional ASCs to enter Buffalo and Detroit later this year. It is also in discussions to acquire several ASCs in Dubai, Demian said.

Moreover, the company is considering buying personalized medicine and longevity practices, as well as a large US-based orthopedic group, the CEO added.

Within the next three years, Praesentia aims to open seven LifeSpan Bioscience surgical centers and 50 LifeSpan Bioscience clinics, at which point the business should be valued at more than USD 1bn, particularly with the incorporation of artificial intelligence into back-end processes, Demian said. The company has invested more than USD 5m in proprietary technology.

In Canada, Praesentia’s Pain Care Clinics provide interventional pain management services for various chronic pain symptoms, while Alfa Scan Diagnostic offers x-ray, ultrasound, bone density testing, MRI, and CT scans.

Praesentia’s new approach is to integrate traditional medical care with advanced regenerative therapies, Demian explained. “The objective is not to replace conventional medicine, but to evolve it, shifting from a reactive model to a proactive, prevention-driven approach that helps patients achieve optimal health and long-term performance.”

Demian, 50, an emergency physician and general and reconstructive surgeon, co-founded Praesentia in 2014. The company has around 170 employees, of whom close to 50 are physicians. It has more than 250,000 active patients.

Praesentia works with law firm Greenberg Traurig in the US and Miller Thomson in Canada. Its accounting firm is BDO.